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ABSTRACT
OBJECTIVE: Describing the prevalence of chronic diseases and associated socioeconomic 
and demographic factors, evaluating the patterns of social distancing and the antibodies 
prevalence against SARS-CoV-2 and COVID-19 symptoms in carriers and non-carriers of 
chronic diseases.
METHODS: Data from 77,075 individuals aged 20 to 59 from three steps of the EPICOVID-19 
Brazil (a nationwide serological survey conducted between May and June, 2021) were assessed. 
The presence of antibodies against SARS-CoV-2 was examined by rapid tests. Self-reported 
prevalence of hypertension, diabetes, asthma, cancer, chronic kidney disease and heart disease 
were investigated. The prevalence of mask use, adherence to isolation measures and antibodies 
were evaluated separately amid carriers and non-carriers of chronic diseases. The prevalence of 
symptoms was analyzed among carriers and non-carriers of chronic diseases with antibodies.
RESULTS: The prevalence of at least one chronic disease was 43%, higher in the Southeast region, 
among white and indigenous individuals, women, less schooled and in lower socioeconomic 
position. The use of masks when leaving home was similar among carriers and non-carriers 
of chronic diseases (98%). The proportion of participants who reported adherence to isolation 
measures was higher amid carriers (15.9%) than non-carriers (24.9%) of chronic diseases. The 
prevalence of antibodies to SARS-CoV-2 was similar amongst carriers and non-carriers (2.4% 
and 2.3%). The prevalence of cough, dyspnea, palpitations and myalgia was significantly higher 
among carriers, but the proportion of symptomatic patients was similar between groups.
CONCLUSION: The prevalence of chronic diseases in Brazil is high and the COVID-19 
pandemic affects carriers and non-carriers of chronic diseases similarly. Carriers present 
more severe forms of COVID-19 and higher prevalence of symptoms. Greater adherence to 
social distancing measures among chronic patients is disassociated from a lower incidence of 
COVID-19 in this group.
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INTRODUCTION
By early April, 2021, about 132 million COVID-19 confirmed cases and 3 million deaths were 
accounted worldwide. The Americas and Europe comprise most of the confirmed cases. Even 
though Brazil accounts for approximately 3% of the global population, it comprises 10% of 
all cases and deaths worldwide1. COVID-19 mortality depends not only on the number of 
incident cases, but also on population factors such as age structure and comorbidity burden 
connected to the development of severe forms of the disease1.
Since the beginning of the pandemic, chronic non-communicable diseases (NCDs) such 
as high blood pressure, diabetes, respiratory diseases and cardiovascular diseases have 
been associated with the greater severity and COVID–19 lethality2–4. A meta-analysis 
including eight studies on the association between NCDs and COVID-19 severity showed 
that chronic obstructive pulmonary disease (COPD) was the strongest predictor of severe 
forms of COVID–19 (odds ratio [OR] = 6.4; 95%CI 2.4–16.9), followed by cardiovascular 
disease (OR = 2.7; 95%CI 1.5–4.8) and hypertension (OR = 1.9; 95%CI 1.4–2.7). Hospitalization 
in intensive care units was even more strongly associated with COPD, cardiovascular 
disease and hypertension, with OR of 17.8 (95%CI 6.5–48.2), 4.4 (95%CI 2.6–7.4) and 3.6 
(95%CI 2.2–5.9)4, respectively. Another meta-analysis evaluated specifically the connection 
between diabetes and COVID-19 severity or lethality, finding a positive association (OR 2.16; 
95%CI 1.74–2.68)5. Chronic kidney disease, cancer, asthma, liver diseases and HIV/AIDS are 
also related to unfavorable outcomes of COVID-19 infections6.
Due to the demographic and epidemiological transition in progress, Brazil displays a 
high load of NCDs7, 8. The prevalence of obesity and physical inactivity, crucial risk factors 
for these morbidities, is also high8,9. This scenario is alarming in the Brazilian COVID-19 
pandemic context, as it increases the risk of severe cases in a country with an elevated 
incidence. Therefore, the assessment of the panorama of NCDs associated with COVID-19 
infection in Brazil is fundamental. This study aims at describing the prevalence of NCDs 
and associated socioeconomic and demographic factors, in addition to evaluating the 
patterns of social distancing and the prevalence of antibodies against SARS-CoV-2 among 
carriers and non-carriers of NCDs, as well as the symptom occurrence among individuals 
with antibodies against SARS-CoV-2 carrying and not carrying NCDs. 
METHODS
We analyzed data from EPICOVID-19 Brazil, a series of national serological surveys carried 
out aiming at evaluating the magnitude, evolution and characteristics of the pandemic. 
The most populous city of each of the 133 geographical intermediate regions, according 
to the Brazilian Institute of Geography and Statistics (IBGE), were selected to take part 
in the study. Multiple stage sampling was carried out in each city, having the 2010 IBGE’s 
urban census sectors as primary sampling units. We selected 25 sectors with probability 
proportional to size in each city. In each sector, 10 households were systematically 
selected. In each household, a resident was drawn and invited to participate in the study. 
In case of refusal, a second resident was drawn. If the second resident had also refused, 
the interviewers would have approached the next household, immediately on the right. 
The same replacement procedure was adopted if the selected household was empty or 
did not open the door to the interviewer. All refusals and substitutions were recorded 
by the field team. 
Each participant answered a questionnaire on socioeconomic and demographic 
characteristics, social distancing, mask use, presence of COVID-19 symptoms, previous 
diagnosis of NCDs, among others. Participants underwent the WONDFO SARS-CoV-2 
rapid Antibody Test (Wondfo Biotech Co., Guangzhou, China), which detects the presence 
of antibodies against SARS-CoV-2 (IgG and IgM). The test was previously validated by 
the responsible research team10,11. The interviewers received standardized training on the 
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questionnaire application, rapid test administration, and results analysis. All positive rapid 
tests and 20% of the negative ones were evaluated by a second observer. EPICOVID-19 
Brazil’s detailed methodology was previously published12.
Data were collected in three EPICOVID-19 Brazil stages, conducted from May 14 to 21 
(n = 25,025), from June 4 to 7 (n = 31,165) and from June 21 to 24 (n = 33,207), 2020. The 
analyses here were restricted to adults aged 20 or older.
To assess the existence of chronic diseases, patients were asked if they had ever been 
diagnosed with hypertension, diabetes, asthma, cancer, chronic kidney disease and heart 
disease (“yes” or “no”). Individuals who reported a diagnosis of one or more NCDs were 
considered carriers of NCDs and will be mentioned in this way throughout the text.
The presence of antibodies against SARS-CoV-2 was evaluated by the rapid test results: 
when the result was positive, the individual was considered to have antibodies against 
the virus. Mask use was assessed by the question “Do you wear a mask when you leave 
your house?” (“yes”, “no” or “I do not leave my house”). Adherence to social distancing was 
assessed by the following questions:
• “How much of the social distancing guidelines recommended by health authorities 
(i. e., staying at home and avoiding contact with other people) do you follow?” (“very 
little”, “little”, “more or less”, “quite a lot” or “mostly isolated from everyone”);
• “How has your daily routine been?” (“I stay at home all the time”, “I leave my house 
only for essential things, such as buying food”, “I go out from time to time to shop and 
stretch my legs”, “I leave my house every day for some activity”, “I go out every day, all 
day, to work or to do other regular activities”);
• “Thinking about the household routine, who has been attending the house?” (“only family 
members who live together, if any, and no one else”, “some close relatives visit once to 
twice a week”, “some close relatives visit almost every day”, “friends, relatives or others 
visit once to twice a week”, “friends, relatives or others visit almost every day”).
To assess the presence of COVID-19 symptoms, participants were asked if they had the 
following symptoms: fever, cough, sore throat, changes in smell or taste, myalgia, twitching, 
headache, breathing difficulties, palpitation, diarrhea and vomiting. Participants who 
reported the occurrence of at least one symptom were considered symptomatic. The recall 
period of questions about symptoms differed between the stages of EPICOVID-19 Brazil. 
The first two stages evaluated the occurrence of symptoms in the 15 days prior to the 
interview and the third stage evaluated the period from March 2020 to the interview date. 
Since antibodies against SARS-Cov-2 become detectable in the rapid test about 15 days after 
infection, the analysis on the occurrence of symptoms was restricted to the participants 
of the third stage.
The evaluated socioeconomic and demographic variables were geographic region (North, 
Northeast, Southeast, South or Midwest), self-reported skin color (white, black, brown, 
yellow or indigenous), gender (female or male), age (in categories) and schooling levels 
(elementary school, high school or higher education). To assess the socioeconomic position 
of households, the National Economic Indicator (IEN) was used. This index was created 
by the analysis of main components based on a set of household characteristics and goods 
(computer, internet access, color television, air conditioning, motor vehicles, cable television, 
number of rooms used for sleeping and number of bathrooms). The first component was 
extracted and divided into quintiles. The first quintile represents the poorest 20% and the 
fifth quintile, the richest 20%13.
The analyses included the sample description and the prevalence calculation of each NCD 
and the prevalence of carriers of NCDs. The prevalence of carriers of NCDs was assessed 
according to region, skin color, gender, age, IEN and schooling levels. The prevalence 
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Table 1. Sociodemographic characteristics and prevalence of chronic non-communicable diseases at 
the EPICOVID-19 Brazil study, stages 1 to 3 (n = 77,075).
n % (95%CI)
Description of sample characteristics
Region
North 13,075 16.8 (16.5–17.2)
Northeast 23,033 29.6 (29.1–30.1)
Southeast 19,359 25.3 (24.8–25.8)
South 13,112 17.3 (16.8–17.8)
Mid-west 8,496 11.0 (10.7–11.4)
Skin color
White 28,387 37.8 (37.2–38.3)
Brown 33,732 44.8 (44.4–45.3)
Black 10,030 13.3 (12.9–13.6)
Yellow 2,132 2.8 (2.7–2.9)
Indigenous 1,046 1.4 (1.3–1.5)
Gender
Male 31,239 40.5 (40.2–40.9)
Female 45,836 59.5 (59.1–59.8)
Age
20–29 13,796 18.3 (18.0–18.6)
30–39 13,726 18.2 (17.9–18.5)
40–49 14,129 18.5 (18.2–18.8)
50–59 14,273 18.5 (18.2–18.8)
60–69 12,062 15.3 (15.1–15.6)
70–79 9,126 11.1 (10.9–11.4)
IEN (in quintiles)
The poorest 18,106 22.7 (22.2–23.2)
2 14,161 18.2 (17.9–18.5)
3 14,748 19.3 (18.9–19.6)
4 14,909 19.7 (19.3–20.0)
The richest 15,143 20.2 (19.6–20.8)
Schooling levels
Elementary school 30,876 39.5 (38.9–40.1)
High school 28,315 37.7 (37.3–38.1)
Higher education 17,013 22.8 (22.2–23.4)
Antibodies against SARS-CoV-2 
Yes 1,824 2.3 (2.2–2.5)
Prevalence of chronic diseases
Hypertension 23,575 30.0 (29.6–30.3)
Diabetes 9,842 12.5 (12.2–12.7)
Asthma 7,266 9.4 (9.2–9.6)
Cancer 2,307 3.0 (2.8–3.1)
Kidney disease 3,128 4.0 (3.8–4.1)
Heart disease 6,354 8.1 (7.9–8.3)
Number of chronic diseases reported
None 42,246 56.2 (55.8–56.6)
One 20,521 27.0 (26.6–27.3)
Two 9,164 11.9 (11.6–12.1)
Three 2,985 3.9 (3.7–4.0)
Four or more 827 1.1 (1.1–1.2)
95%CI: 95% confidence interval; IEN: Indicador Econômico Nacional (National Economic Indicator).
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of mask use and adherence to social isolation measures, as well as the prevalence of 
individuals with antibodies against SARS-Cov-2, were calculated separately for carriers 
and non-carriers of NCDs. Finally, the prevalence of symptoms for COVID-19 between 
carriers and non-carriers of NCDs with antibodies against SARS-Cov-2 was calculated. 
For all proportions, 95% confidence intervals were calculated. We obtained p-values 
by a Chi-square test for heterogeneity or, for ordinal categorical variables, linear trend, 
considering a significance level of 5%. All analyses were conducted in Stata 16, considering 
the effect of sample design.
This study respected all the ethical precepts and legislation governing research with 
human beings and was approved by the National Commission for Research Ethics (CAAE 
30721520.7.1001.5313). All participants signed the informed consent form.
Table 2. Prevalence of one or more chronic non-communicable diseases, according to socioeconomic 
and demographic characteristics at the EPICOVID-19 Brazil study, stages 1 to 3 (n = 77,075).
% (95%CI)












Gender p < 0.001a
Male 39.5 (38.9–40.1)
Female 47.4 (47.0–47.9)






70 or older 78.3 (77.5–79.2)
IEN (in quintiles) p < 0.001b




The richest 42.1 (41.3–42.9)
Schooling levels p < 0.001b
Elementary school 57.0 (56.4–57.6)
High school 35.6 (35.0–36.2)
Higher education 35.0 (34.2–35.7)
95%CI: 95% confidence interval; IEN: Indicador Econômico Nacional (National Economic Indicator).
a Chi-square test of heterogeneity.
b Linear trend test.
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RESULTS
We analyzed EPICOVID-19 Brazil’s data from 77,075 participants aged 20 or older. Most 
were female (59%) and non-white (62%). About a quarter were older adults (aged 60 or older). 
Around 40% of the participants reported having attended elementary school (39%) and lived 
in the region. Considering the three stages of the study, the crude proportion of participants 
with antibodies against SARS-CoV-2 was 2.3% (95%CI 2.3-2.5). Circa 45% of those reported 
carrying one or more NCDs. The most prevalent NCDs were arterial hypertension (30%), 
followed by diabetes (13%), asthma (9%) and heart disease (8%) (Table 1).
Table 2 shows the prevalence of one or more NCDs according to socioeconomic and 
demographic characteristics. The prevalence was higher in the Southeast and South (48%), 
among indigenous people (47%), women (47%) and individuals with lower schooling levels 
(57%). The prevalence of one or more NCDs presented an inverse relationship with age and 
quintiles of the IEN. All differences were statistically significant (p-value < 0.001).
The results on social distancing are presented in Table 3. Around 25% of individuals carrying 
one or more NCDs reported being isolated from virtually everyone. Among non-carriers, 
this percentage was 15%. Regarding the daily activities, 13% of those with one or more NCDs 
reported leaving their houses every day to work, while among those without NCDs this 
proportion was 25%. Both among carriers and non-carriers, the proportion that reported 
that only the residents themselves attended the household was approximately 50%. A higher 
proportion of carriers with one or more NCDs reported receiving close relatives (44%) when 
compared to non-carriers (39%).
Except for individuals who reported a diagnosis of cancer, the differences in the prevalence 
of antibodies against SARS-CoV-2 between carriers and non-carriers of NCDs were minimal 
(Table 4). Table 5 shows the prevalence of COVID-19 symptoms among individuals with 
antibodies against SARS-CoV-2, both carriers and non-carriers of NCDs. Carriers of one or 
Table 3. Social distancing and mask use between carriers and non-carriers of chronic non-communicable diseases (NCDs) at the EPICOVID-19 




Carrier of one or 
more NCDs pa
% (95%CI) % (95%CI)
Adherence to insolation
Very little 3,740 8.9 (8.6–9.2) 2.112 6.3 (6.1–6.6) < 0.001
Little 4,449 10.6 (10.3–10.9) 2.621 7.9 (7.6–8.2)
More or less 11,637 27.7 (27.2–28.1) 7.533 22.6 (22.2–23.1)
Quite a lot 15,510 36.9 (36.4–37.4) 12.706 38.2 (37.6–38.8)
Isolated 6,686 15.9 (15.5–16.3) 8.300 24.9 (24.5–25.4)
Daily activities
Stays at home all the time 4,983 11.8 (11.5–12.2) 7.930 23.7 (23.3–24.2) < 0.001
Leaves only for essential things like buying food 19,676 46.7 (46.2–47.2) 16.482 49.3 (48.8–49.9)
Leaves from time to time for shopping and stretch the legs 4,144 9.8 (9.5–10.1) 3.114 9.3 (9.0–9.7)
Leaves every day for some activity 2,884 6.8 (6.6–7.1) 1.546 4.6 (4.4–4.9)
Leaves every day. all day. to work or other regular activity 10,440 24.8 (24.3–25.3) 4.341 13.0 (12.6–13.4)
People who attend the house
Only family members who live together. if any. and no one else 20,903 49.9 (49.3–50.5) 15.354 46.3 (45.6–46.9) < 0.001
Some close relatives visit once or twice a week 13,349 31.9 (31.4–32.4) 11.585 34.9 (34.4–35.5)
Some close relatives visit almost every day 2,993 7.1 (6.9–7.4) 3.064 9.2 (8.9–9.6)
Relatives or other people visit once to twice a week 2,895 6.9 (6.7–7.2) 1.978 6.0 (5.7–6.2)
Relatives or other people visit almost every day 1,738 4.2 (3.9–4.4) 1.208 3.6 (3.4–3.9)
Mask use outside the house 41,341 98.0 (97.8–98.1) 32.537 97.2 (97.0–97.3) < 0.001
95%CI: 95% confidence interval.
a Chi-square test of heterogeneity.
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more NCDs reported 50% more twitching occurrences than non-carriers, in addition a to 
a 26% and 29% higher occurrence of coughing and dyspnea, respectively. Myalgia was 16% 
more prevalent among carriers of NCDs. The prevalence of the other evaluated symptoms 
and the proportion of asymptomatic individuals were statistically similar. 
DISCUSSION
Our results showed that Brazil has a high burden of chronic diseases. Despite greater 
adherence to social distancing measures among carriers of NCDs, the prevalence of 
antibodies against SARS-CoV-2 was similar between groups. 
Each morbidity assessed here depicted a higher prevalence when compared to the National 
Health Survey results, in which 21% of participants reported a diagnosis of hypertension 14 
(versus 30% in the present study), 6.2% of diabetes15 (versus 13%), 4.4% of asma16 (versus 
9%), 1.8% of cancer17 (versus 3%), 1.4% of chronic kidney disease18 (versus 4%) and 4.2% 
heart disease19(versus 8%). The results were also higher than the 2018 VIGITEL ones, which 
estimated self-reported prevalence diagnosis of hypertension and diabetes of 25% and 
8%, respectively8. The higher prevalence of NCDs evidenced here is possibly related to the 
Table 4. Prevalence of antibodies against SARS-CoV-2 between carriers and non-carriers of chronic 




n % (95%CI) n % (95%CI)
Hypertension 1,263 2.4 (2.2–2.5) 552 2.3 (2.1–2.6) 1.0 (0.9–1.1) 0.797
Diabetes 1,542 2.3 (2.2–2.4) 265 2.7 (2.4–3.0) 1.2 (1.0–1.3) 0.019
Asthma 1,664 2.4 (2.3–2.5) 154 2.1 (1.8–2.5) 0.9 (0.8–1.0) 0.148
Cancer 1,794 2.4 (2.3–2.5) 22 1.0 (0.6–1.4) 0.4 (0.3–0.6) < 0.001
Kidney disease 1,732 2.4 (2.2–2.5) 82 2.6 (2.1–3.3) 1.1 (0.9–1.4) 0.332
Heart disease 1,710 2.4 (2.3–2.6) 101 1.6 (1.3–1.9) 0.7 (0.5–0.8) < 0.001
One or more NCDs 1,009 2.4 (2.2–2.6) 769 2.3 (2.1–2.5) 1.0 (0.9–1.1) 0.403
95%CI: 95% confidence interval; PR: prevalence ratio. 
a Reference: non-carriers of chronic diseases.
Table 5. Prevalence of self-reported symptoms among individuals with antibodies against SARS-CoV-2 
with and without chronic non-communicable diseases (NCDs) at the EPICOVID-19 Brazil study, Step 3.
Symptom
Non-carriers of NCDs Carriers of NCDs
PR (95%CI)a pb
n % (95%CI) n % (95%CI)
Fever 242 50.8 (45.6–56.0) 196 55.2 (49.3–61.0) 0.9 (0.9–1.2) 0.212
Sore throat 174 36.6 (31.9–41.5) 124 34.9 (29.6–40.6) 1.0 (0.8–1.2) 0.629
Cough 214 45.1 (40.2–50.0) 202 56.6 (50.7–62.3) 1.3 (1.1–1.5) 0.001
Dyspnea 111 23.4 (19.4–27.8) 107 30.1 (24.8–35.9) 1.3 (1.0–1.6) 0.030
Palpitations 80 16.9 (13.4–21.1) 103 29.1 (24.0–34.8) 1.7 (1.3–2.3) 0.381
Anosmia 285 60.0 (55.0–64.8) 223 63.0 (57.3–68.3) 1.1 (0.9–1.2) 0.381
Diarrhea 137 28.8 (24.3–33.7) 108 30.3 (25.1–36.0) 1.1 (0.8–1.3) 0.645
Vomiting 36 7.6 (5.4–10.6) 36 10.1 (6.9–14.4) 1.3 (0.8–2.2) 0.203
Myalgia 233 46.9 (42.2–51.8) 192 54.4 (48.4–60.3) 1.2 (1.0–1.3) 0.034
Twitching 90 19.1 (15.2–23.7) 104 29.2 (24.3–34.7) 1.5 (1.1–2.0) 0.001
Headache 295 62.0 (57.0–66.7) 202 56.6 (50.8–62.2) 0.9 (0.8–1.0) 0.116
Symptomatic 403 86.9 (83.2–89.8) 313 90.0 (86.5–94.1) 1.1 (1.0–1.1) 0.067
95%CI: 95% confidence interval; PR: prevalence ratio. 
a Reference: non-carriers of chronic diseases.
b Chi-square test of heterogeneity.
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high percentage of people aged 60 or older in the sample (26%), higher than the percentage 
of this group among Brazilians in general (14%). As shown in Table 2 and corroborated by 
other studies, the prevalence of NCDs increases with age7.
There are two probable reasons for the higher proportion of older adults in this study 
compared to the rest of the population. Possibly because of the pandemic, most of the older 
adults living in the households included in the sample were present at the time of the study, 
unlike younger people. A population-based study on social distancing patterns conducted 
in Rio Grande do Sul showed that older adults are more likely to stay home or leave their 
houses only for essential activities (80%) than individuals aged between 20 and 59 (60%)20. 
Another relevant aspect is that we assessed 133 sentinel cities, which are more populous, 
have a higher Human Development Index and greater access to health services than the 
cities excluded from the study. Because of those characteristics, residents of these cities 
tend to live longer, so the proportion of older adults tends to be higher.
The mask use and physical distancing drastically reduce the transmission of COVID-1921. 
The percentage of participants who reported wearing a mask when leaving home was 
almost universal in both groups (98%). However, we must consider an information bias when 
interpreting the results. Knowing the legal requirements of mask use during the pandemic, 
participants might have reported that they always use masks because this is the correct 
behavior in the current context.
Carriers of NCDs reported greater adherence to social isolation and universal mask use 
when leaving home. Nevertheless, the prevalence of antibodies against SARS-CoV-2 in 
this group was similar to that evidenced among non-carriers of NCDs. This may suggest 
the occurrence of intra-household transmission of COVID-19, since the proportion of 
participants who are visited by close relatives and friends was about 50% in both groups. 
COVID-19 transmission in clusters, especially family ones, plays an important role in the 
rapid spread of the disease22,23. The almost universal mask use outside the house is probably 
rejected at home. Thus, family members who adhere less to isolation and, therefore, present 
similar infection levels to those evidenced among non-carriers of NCDs would contaminate 
the carrier ones. However, the adoption of preventive measures such as wearing a mask and 
physical distancing at home, as well as in-house social distancing, was not evaluated in 
this study, which prevents us from formally testing this hypothesis. Besides, as previously 
mentioned, mask use might be overestimated or masks may be worn incorrectly. We must 
also consider reverse causation. Participants with antibodies against SARS-CoV-2 may have 
switched to wearing a mask after experiencing COVID-19.
The analysis on the symptom prevalence was restricted to individuals with antibodies 
against SARS-CoV-2. Among the evaluated COVID-19 symptoms, the prevalence of 
cough, dyspnea, myalgia and twitching was higher among carriers of NCDs than among 
non-carriers. Despite the higher prevalence of these symptoms among carriers of NCDs, 
we must consider an eventual non-responder bias. COVID-19 tends to evolve into severe 
forms in carriers of NCDs2–4, and severe cases tend to leave after-effects even months after 
the disease24. Therefore, carriers of NCDs possibly developed severe forms of the disease 
with prolonged after-effects and presented a higher refusal rate, which may have decreased 
the difference in the symptom prevalence amid groups. In addition, COVID-19 mortality 
among carriers of NCDs is higher when compared to non-carriers. Hence, participants 
with a positive result on the rapid test here may represent, to some extent, surviving cases.
This study has other limitations. We assessed data from 133 sentinel cities, which are more 
developed, have a better health services structure and higher Human Development Index 
than the cities excluded from the sample. We excluded residents of rural areas, which 
correspond to 15% of the country’s population. We ignored the adoption of protective 
behaviors, such as mask use and physical distancing during the interaction with close 
acquaintances, as well as adherence to distancing recommendations during daily in-house 
activities. The evaluation of self-reported symptoms may have introduced classification 
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bias. However, we revealed the rapid test results only at the end of the interview, so the 
participants were blind to them while answering the questionnaire. This possibly decreased 
the bias likelihood.
The strengths of this study include: its national scope, being one of the world’s largest 
COVID-19 serological surveys in sample size and territorial coverage carried out so far; the 
blinding of participants about the test results; and the multidimensional character of the 
research, which evaluates both seroprevalence and several individual aspects related to 
COVID-19, such as the presence of comorbidities, adoption of preventive measures against 
COVID-19 and symptom occurrence.
The results here improve the understanding of the pandemic dynamics in Brazil, where 
the NCDs burden, as well as incidence and mortality due to COVID-19 are high. Since 2016 
Brazil has been suffering from fiscal austerity policies, which constricted the Unified Health 
System (SUS). Consequently, the supply and quality of actions and services decreased, 
compromising the health of a large portion of Brazilians who depend on it25. Combined with 
this context, the absence of a national policy to deal with COVID-19 based on scientific 
evidence26,27 contributes substantially to Brazil being placed among the top countries at 
the global ranking of new infections and deaths from the disease1.
The pandemic control in Brazil requires large-scale immunization of the population. 
Immunization against COVID-19 in Brazil began in mid-January 2021, firstly applied to 
health professionals working on the front line against the virus. Carriers of NCDs are part 
of the third priority group at the Brazilian Ministry of Health’s National Immunization 
Plan28. Despite having one of the largest and most efficient immunization networks in the 
world, vaccination in Brazil is still incipient and the country currently ranks 78th in the 
world ranking of countries with the highest number of citizens vaccinated against the 
disease (10.3 /100 inhabitants)29. The immunization of NCDs carriers lacks a prediction.
In conclusion, the prevalence of chronic diseases in Brazil is high and the COVID-19 
pandemic affects carriers and non-carriers of chronic diseases similarly. Carriers of 
NCDs present more severe forms of COVID-19 and higher symptom prevalence. Greater 
adherence to social distancing measures among carriers of NCDs is disassociated from a 
lower incidence of COVID-19 in this group. More than ever, we must stimulate protective 
measures such as physical distancing and wearing a mask at home in this group.
REFERENCES
1. World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. Geneva;  
2021 [cited 2021 Feb 1]. Available from: https://covid19.who.int/
2. Gold MS, Sehayek D, Gabrielli S, Zhang X, McCusker C, Ben-Shoshan M. COVID-19 and 
comorbidities: a systematic review and meta-analysis. Postgrad Med. 2020;132(8):749-55. 
https://doi.org/10.1080/00325481.2020.1786964
3. Wang Z, Deng H, Ou C, Liang J, Wang Y, Jiang M, et al. Clinical symptoms, comorbidities 
and complications in severe and non-severe patients with COVID-19: a systematic review 
and meta-analysis without cases duplication. Medicine (Baltimore}. 2020;99(48):e23327. 
https://doi.org/10.1097/MD.0000000000023327
4. Jain V, Yuan JM. Predictive symptoms and comorbidities for severe COVID-19 and intensive care 
unit admission: a systematic review and meta-analysis. Int J Public Health. 2020;65(5):533-46. 
https://doi.org/10.1007/s00038-020-01390-7
5. Kumar A, Arora A, Sharma P, Anikhindi SA, Bansal N, Singla V, et al. Is diabetes mellitus 
associated with mortality and severity of COVID-19? A meta-analysis. Diabetes Metab Syndr. 
2020;14(4):535-45. https://doi.org/10.1016/j.dsx.2020.04.044
6. Ssentongo P, Ssentongo AE, Heilbrunn ES, Ba DM, Chinchilli VM, Ba DM. Association 
of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 
mortality: a systematic review and meta-analysis. PloS One. 2020;15(8):e0238215. 
https://doi.org/10.1371/journal.pone.0238215
10
Chronic Diseases and COVID-19 in Brazil Mesenburg MA et al.
https://doi.org/10.11606/s1518-8787.2021055003673
7. Instituto Brasileiro de Geografia e Estatística, Diretoria de Pesquisas, Coordenação  
de Trabalho e Rendimento. Pesquisa Nacional de Saúde. 2013: percepção do estado de saúde, 
estilos de vida e doenças crônicas: Brasil, grandes regiões e unidades da federação. Rio de 
janeiro: IBGE; 2014.
8. Ministério da Saúde (BR), Secretaria de Vigilância em Saúde, Departamento de Análise em 
Saúde e Vigilância de Doenças não Transmissíveis. Vigitel Brasil 2018: vigilância de fatores de 
risco e proteção para doenças crônicas por inquérito telefônico nas capitais dos 26 estados 
brasileiros e no Distrito Federal em 2018. Brasília, DF; 2019.
9. World Health Organization. Noncommunicable diseases country profiles 2018. Geneva: 
WHO; 2018 [cited 2021 Feb 18]. Available from: https://www.who.int/nmh/publications/ncd-
profiles-2018/en/
10. Pellanda LC, Ros Wendland EM, McBride AJA, Tovo-Rodrigues L, Ferreira MRA, 
Dellagostin OA, et al. Sensitivity and specificity of a rapid test for assessment of exposure 
to SARS-CoV-2 in a community-based setting in Brazil. medRxiv [Preprint]. 2020. 
https://doi.org/10.1101/2020.05.06.20093476
11. Silveira MF, Mesenburg MA, Dellagostin OA, Oliveira NR, Maia MAC, Santos FDS, et al. 
Time-dependent decay of detectable antibodies against SARS-CoV-2: a comparison of 
ELISA with two batches of a lateral-flow test [Preprint]. Rochester, NY: SSRN; 2021. 
https://doi.org/10.2139/ssrn.3757411
12. Hallal PC, Barros FC, Silveira MF, Barros AJD, Dellagostin OA, Pellanda LC, et al. EPICOVID-19 
protocol: repeated serological surveys on SARS-CoV-2 antibodies in Brazil. Cienc Saude 
Coletiva. 2020;25(9):3573-8. https://doi.org/10.1590/1413-81232020259.25532020
13. Barros AJD, Victora CG. A nationwide wealth score based on the 2000 
Brazilian demographic census. Rev Saude Publica. 2005;39(4):523-9. 
https://doi.org/10.1590/s0034-89102005000400002
14. Malta DC, Gonçalves RPF, Machado IE, Freitas MIF, Azeredo C, Szwarcwald CL.  
Prevalence of arterial hypertension according to different diagnostic criteria 
National Health Survey. Rev Bras Epidemiol. 2018;21 Supl 1:e180021. 
https://doi.org/10.1590/1980-549720180021.supl.1
15. Malta DC, Bernal RTI, Iser BPM, Szwarcwald CL, Duncan BB, Schmidt MI. Factors associated 
with self-reported diabetes according to the 2013 National Health Survey. Rev Saude Publica. 
2017;51 Supl 1:12s. https://doi.org/doi:10.1590/S1518-8787.2017051000011
16. Menezes AMB, Wehrmeister FC, Horta B, Szwarcwald CL, Vieira ML, Malta DC. Prevalence 
of asthma medical diagnosis among Brazilian adults: National Health Survey, 2013. Rev Bras 
Epidemiol. 2015;18 Supl 2:204-13. https://doi.org/10.1590/1980-5497201500060018
17. Oliveira MM, Malta DC, Guauche H, Moura L, Silva GA. Estimated number of people  
diagnosed with cancer in Brazil: data from the National Health Survey, 2013. Rev Bras 
Epidemiol. 2015;18 Supl 2:146-57. https://doi.org/doi:10.1590/1980-5497201500060013
18. Aguiar LK, Prado RR, Gazzinelli A, Malta DC. Factors associated with chronic kidney disease: 
epidemiological survey of the National Health Survey. Rev Bras Epidemiol. 2020;23:e200044. 
https://doi.org/10.1590/1980-549720200044 
19. Gonçalves RPF, Haikal DS, Freitas MIF, Machado IE, Malta DC. Self-reported medical diagnosis 
of heart disease and associated risk factors: National Health Survey. Rev Bras Epidemiol. 
2019;22 Supl 2:E190016. https://doi.org/10.1590/1980-549720190016.supl.2
20. Barros AJD, Victora CG, Menezes AMB, Horta BL, Hartwig F, Victora G, et al. Social distancing 
patterns in nine municipalities of Rio Grande do Sul, Brazil: the Epicovid19/RS study. Rev Saude 
Publica. 2020;54:75. https://doi.org/10.11606/s1518-8787.2020054002810
21. Chu DK, Akl EA, Duda S, Solo K, Yaacoub S, Schünemann HJ; COVID-19 Systematic 
Urgent Review Group Effort (SURGE) study authors. Physical distancing, face masks, 
and eye protection to prevent person-to-person transmission of SARS-CoV-2 and 
COVID-19: a systematic review and meta-analysis. Lancet. 2020;395(10242):1973-87. 
https://doi.org/10.1016/S0140-6736(20)31142-9
22. Wang Z, Ma W, Zheng X, Wu G, Zhang R. Household transmission of SARS-CoV-2. J Infec. 
2020;81(1):179-82. https://doi.org/10.1016/j.jinf.2020.03.040
23. Liu T, Gong D, Xiao J, Hu J, He G, Rong Z, et al. Cluster infections play important roles in the 
rapid evolution of COVID-19 transmission: a systematic review. Int J Infect Dis. 2020;99:374-80. 
https://doi.org/10.1016/j.ijid.2020.07.073
11
Chronic Diseases and COVID-19 in Brazil Mesenburg MA et al.
https://doi.org/10.11606/s1518-8787.2021055003673
24. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 
in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220-32. 
https://doi.org/10.1016/S0140-6736(20)32656-8
25. Malta DC, Duncan BB, Barros MBA, Katikireddi SV, Souza FM, Silva AG, et al. Fiscal austerity 
measures hamper noncommunicable disease control goals in Brazil. Cienc Saude Coletiva. 
2018;23(10):3115-22. https://doi.org/10.1590/1413-812320182310.25222018
26. The Lancet. COVID-19 in Brazil: “So what?”. Lancet. 2020;395(10235):1461. 
https://doi.org/10.1016/S0140-6736(20)31095-3
27. Hallal PC. SOS Brazil: science under attack. Lancet. 2021;397(10272):373-4. 
https://doi.org/ 10.1016/S0140-6736(21)00141-0
28. Ministério da Saúde (BR). Plano Nacional de Imunização contra COVID-19. Brasília, DF; 2020.
29. Global Change Data Lab. Our World in Data: Coronavirus (COVID-19) vaccinations. Oxford 
(UK); 2021 [cited 2021 Apr 6]. Available from: https://ourworldindata,org/covid-vaccinations
Funding: This study was funded by the Brazilian Ministry of Health, Instituto Serrapilheira, Associação Brasileira 
de Saúde Coletiva and JBS Fazer o Bem Faz Bem.
Authors’ Contributions: Study design and planning: PCH, AMBM, AJDB, BLH, FCB, FPH, MFS. Study execution: 
MAM, PCH, AMBM, AJDB, BLH, FCB, FPH, NJ, MFS. Data analysis and interpretation: MAM. Manuscript writing: 
MAM. Critical review of the manuscript: PCH, AMBM, AJDB, BLH, FCB, FPH, NJ, MFS. Approval of the final 
version of the manuscript: MAM, PCH, AMBM, AJDB, BLH, FCB, FPH, NJ, MFS.
Conflict of Interest: The authors declare no conflict of interest.
